SCHEMBL21580684

SCHEMBL21580684

Cc1ccc(Oc2cc(N3C(=O)NC(C)(C)C3=O)ccn2)cc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 11/20 0.51
PLA2G7 Q13093 1/20 0.38
LMNA P02545 2/20 0.37
TSHR P16473 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
PGR P06401 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX12 P18054 1/20 0.37
NFKB1 P19838 1/20 0.37
CYP2C19 P33261 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
PDE4D Q08499 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21580770 0.89 AR (0.39) ARPLA2G7LMNATSHRMAPK1
SCHEMBL21580622 0.86 AR (0.47) ARLMNATSHRSMN1; SMN2MEN1
SCHEMBL21580616 0.86 AR (0.50) ARPLA2G7LMNATSHRSMN1; SMN2
SCHEMBL31690572 0.84 AR (0.38) ARPLA2G7LMNATSHRSMN1; SMN2
SCHEMBL21610136 0.84 AR (0.38) ARPLA2G7LMNATSHRSMN1; SMN2
SCHEMBL21581566 0.82 AR (0.50) ARLMNATSHRSMN1; SMN2MEN1
SCHEMBL21580766 0.81 AR (0.49) ARPLA2G7LMNATSHRSMN1; SMN2
SCHEMBL21610141 0.79 AR (0.40) ARPLA2G7LMNATSHRSMN1; SMN2
SCHEMBL21580686 0.79 ALOX15 (0.53) ARLMNASMN1; SMN2MAPT
SCHEMBL31221186 0.78 AR (0.39) ARLMNASMN1; SMN2RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12090146-B2 Substituted-pyridinyl compounds and uses thereof BIONOMICS LIMITED (AU) 2024-09-17 US disclosed
EP-3853216-B1 3-[2-(PHENOXY)-4-PYRIDYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DYSFUNCTION AND CNS DISORDERS BIONOMICS LTD (AU) 2024-09-11 EP disclosed
EP-3853216-A1 SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF Bionomics Limited (AU) 2021-07-28 EP disclosed
WO-2019222816-A1 SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF BIONOMICS LIMITED (AU) 2019-11-28 WO disclosed
WO-2019222816-A1 SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF BIONOMICS LIMITED (AU) 2019-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12090146-B2 Substituted-pyridinyl compounds and uses thereof GABRE, GAP43, GRIN2A AR 4818/4885PLA2G7 3090/4885LMNA 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.